Sign up
Log in
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Share
Listen to the news

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Barclays analyst Dan Levy downgraded the rating for General Motors Company (NYSE:GM) from Overweight to Equal-Weight and lowered the price target from $70 to $40. General Motors shares closed at $45.14 on Monday. See how other analysts view this stock.
  • Baird analyst Michael Ha downgraded HCA Healthcare, Inc. (NYSE:HCA) from Outperform to Neutral and cut the price target from $396 to $336. HCA Healthcare shares closed at $340.62 on Monday. See how other analysts view this stock.
  • Jefferies analyst Amy Li downgraded the rating for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) from Buy to Hold and cut the price target from $8 to $0.7. Ironwood Pharmaceuticals shares closed at $0.6479 on Monday. See how other analysts view this stock.
  • Jones Trading analyst Catherine Novack downgraded the rating for Rallybio Corporation (NASDAQ:RLYB) from Buy to Hold. Rallybio shares closed at $0.2702 on Monday. See how other analysts view this stock.
  • Barclays analyst Dan Levy downgraded Mobileye Global Inc. (NASDAQ:MBLY) from Overweight to Equal-Weight and cut the price target from $22 to $14. Mobileye Global shares closed at $12.94 on Monday.  See how other analysts view this stock.

Considering buying GM stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.